Alterity Therapeutics Limited
ATHE · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5 | $4 | $4 | $5 |
| % Growth | 35.3% | 2.6% | -23.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $5 | $4 | $4 | $5 |
| % Margin | 97.7% | 94.7% | 92.7% | 92.9% |
| R&D Expenses | $14 | $19 | $13 | $15 |
| G&A Expenses | $5 | $5 | $5 | $5 |
| SG&A Expenses | $5 | $5 | $5 | $6 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20 | $23 | $18 | $20 |
| Operating Income | -$15 | -$20 | -$15 | -$16 |
| % Margin | -268% | -487.7% | -373.7% | -302.6% |
| Other Income/Exp. Net | $2 | $1 | $1 | $3 |
| Pre-Tax Income | -$12 | -$19 | -$14 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12 | -$19 | -$14 | -$13 |
| % Margin | -223.4% | -475.8% | -352.5% | -250.7% |
| EPS | -1.14 | -3.12 | -3.42 | -3.18 |
| % Growth | 63.5% | 8.8% | -7.5% | – |
| EPS Diluted | -1.14 | -3.12 | -3.42 | -3.18 |
| Weighted Avg Shares Out | 11 | 6 | 4 | 4 |
| Weighted Avg Shares Out Dil | 11 | 6 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$15 | -$20 | -$15 | -$17 |
| % Margin | -269% | -486.9% | -372.8% | -339.5% |